Related Experiment Video
Updated: Jun 23, 2026
09:52
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)
Published on: April 19, 2013
ADAM9 Genetic Variants and Their Role in Modulating Enzyme Activity in Diabetes and Metabolic Traits
Hana Drobiova1, Fahd Al-Mulla2, Rabeah Al-Temaimi1
1Department of Pathology, College of Medicine, Kuwait University, Jabriya, Kuwait.
Journal of Diabetes Research
|May 7, 2025
Summary
Genetic variations in ADAM9 (a disintegrin and metalloproteinase Domain 9) are linked to metabolic syndrome traits. Specific ADAM9 variants show reduced activity, potentially increasing the risk for Type 2 diabetes and impacting metabolic health.
Area of Science:
- Genetics
- Metabolic Disorders
- Molecular Biology
Background:
- A disintegrin and metalloproteinase Domain 9 (ADAM9) is a proteinase with diverse biological roles.
- Its specific involvement in metabolic syndrome pathophysiology and the association with its genetic variants are not well-established.
- Limited research exists on ADAM9 polymorphisms and their link to metabolic traits.
Purpose of the Study:
- To investigate the association between ADAM9 genetic variants and metabolic syndrome traits in an adult Kuwaiti cohort.
- To identify specific ADAM9 polymorphisms related to metabolic health and diabetes risk.
Main Methods:
- Genome-wide association study (GWAS) to identify potential ADAM9 variants.
- Replication study to confirm associations found in the initial GWAS.
- Functional analysis to assess the impact of identified variants on protein activity.
Main Results:
- Two ADAM9 variants, ADAM9-E76K (rs61753672) and ADAM9-P750L (rs144750648), were associated with metabolic traits.
- ADAM9-P750L was confirmed to be associated with HbA1c and showed new links to systolic blood pressure, waist-to-hip ratio, fasting blood glucose, triglycerides, and cholesterol.
- Functional assays indicated reduced proteolytic activity for both identified variants.
Conclusions:
- ADAM9 variants may play a significant role in the development of metabolic syndrome and Type 2 diabetes.
- The reduced proteolytic activity of these variants could contribute to metabolic dysregulation and increased diabetes risk.
More Related Videos
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...